Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) — ResearchAndMarkets.com has released the “Gene Therapy on Neurological Diseases Market Report 2025.” The market for gene therapy focused on neurological diseases is projected to increase from $3.13 billion in 2024 to $3.55 billion in 2025, representing a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth include a rising prevalence of neurological disorders, heightened demand for personalized medicine, increased investments in biotechnology, and a growing number of gene therapy approvals.
Looking ahead, the market is expected to reach $5.76 billion by 2029, with a CAGR of 12.9%. This anticipated growth is attributed to expanding global clinical trial activities, enhanced healthcare infrastructure, and an increasing awareness of rare diseases.
Notable trends include advancements in remote patient monitoring technologies, innovative vector manufacturing, automation in biomanufacturing, and the use of genomic screening in clinical practices.
The report highlights the significant rise in neurological disorders, predominantly in aging populations, which may drive growth in this market. Examples cited include a report from the UK’s National Health Service indicating over 487,000 dementia cases as of June 2024.
Key industry players are developing advanced viral delivery systems, such as adeno-associated virus vectors, to enhance treatment efficacy. For instance, PTC Therapeutics Inc. received FDA approval in November 2024 for a gene therapy addressing aromatic L-amino acid decarboxylase deficiency, demonstrating sustained therapeutic benefits.
The report provides insights into market characteristics, growth projections, and competitive landscapes.
- Why it matters: The growth in the gene therapy market indicates potential advancements in treatment options for neurological disorders, impacting patient care and quality of life. Businesses may find new opportunities in biotechnology research and personalized medicine.
- The latest: PTC Therapeutics Inc. received FDA approval for a gene therapy related to AADC deficiency in November 2024, highlighting advancements in treatment options.
Source: https://www.globenewswire.com/news-release/2025/10/06/3161833/0/en/Advanced-Viral-Delivery-Systems-Revolutionizing-Gene-Therapy-for-Neurological-Disorders.html
Source: https://www.globenewswire.com/news-release/2025/10/06/3161833/0/en/Advanced-Viral-Delivery-Systems-Revolutionizing-Gene-Therapy-for-Neurological-Disorders.html